RICHMOND, Calif. - Californer -- DeepThink Health, Inc., a technology innovator in advanced analytics and artificial intelligence for precision medicine, announced today that Intermountain Healthcare is strengthening its cross-organizational Molecular Tumor Board with the adoption of DeepThink's Precision Tumor Board Solution.
The Precision Tumor Board Solution from DeepThink delivers a streamlined workflow and collaborative learning system that supports multi-organizational and national tumor boards and enables multi-disciplinary clinicians to participate synchronously or asynchronously, in-person or remotely, and via web or mobile applications. With DeepThink's smart search and cohort analytics, clinicians can compare a specific patient to similar patients and analyze their outcome and prognosis within the institution or across broader evidence sharing networks. The solution enables evidence-based decision making for molecular testing, therapy selection, and clinical trial matching. It provides quality and compliance reporting, as well as outcome analytics to monitor consistency in care and value-based performance.
More on The Californer
"We are excited to partner with DeepThink as we continue to advance our efforts in precision medicine." said Lincoln D. Nadauld, MD, Vice President of Precision Health for Intermountain Healthcare. "DeepThink's solutions enhance our ability to scale precision medicine practice by simplifying access to complex health data, liberating key insights from real-world data, and supporting tumor board management with real-time access for clinicians."
"We're pleased to be expanding our working relationship with Intermountain Healthcare, one of the world's leading precision medicine programs," said David C. Dvorak, Chairman and Chief Executive Officer of DeepThink Health. "Because cancer is driven by genetic change, sophisticated solutions are needed at the point of care in order to incorporate clinical and molecular insights into patient treatment decisions. Through this multi-year arrangement, Intermountain is deploying the DeepThink technology that is specifically designed to address this need. We look forward to working closely with Intermountain as we strive to bring the full promise of precision medicine to the treatment of patients."
For more information visit www.deepthinkhealth.com
The Precision Tumor Board Solution from DeepThink delivers a streamlined workflow and collaborative learning system that supports multi-organizational and national tumor boards and enables multi-disciplinary clinicians to participate synchronously or asynchronously, in-person or remotely, and via web or mobile applications. With DeepThink's smart search and cohort analytics, clinicians can compare a specific patient to similar patients and analyze their outcome and prognosis within the institution or across broader evidence sharing networks. The solution enables evidence-based decision making for molecular testing, therapy selection, and clinical trial matching. It provides quality and compliance reporting, as well as outcome analytics to monitor consistency in care and value-based performance.
More on The Californer
- Tecan expands presence in the United States with new distribution agreement
- Scramble New Fiction Novel by Fred Williams
- Just Say No to Fabric and Cloth Masks
- Presidio Identity Aims to Eliminate Identity Theft, Financial Fraud with Innovative Trust and Iden
- California: Governor Newsom Announces Appointments 8.12.20
"We are excited to partner with DeepThink as we continue to advance our efforts in precision medicine." said Lincoln D. Nadauld, MD, Vice President of Precision Health for Intermountain Healthcare. "DeepThink's solutions enhance our ability to scale precision medicine practice by simplifying access to complex health data, liberating key insights from real-world data, and supporting tumor board management with real-time access for clinicians."
"We're pleased to be expanding our working relationship with Intermountain Healthcare, one of the world's leading precision medicine programs," said David C. Dvorak, Chairman and Chief Executive Officer of DeepThink Health. "Because cancer is driven by genetic change, sophisticated solutions are needed at the point of care in order to incorporate clinical and molecular insights into patient treatment decisions. Through this multi-year arrangement, Intermountain is deploying the DeepThink technology that is specifically designed to address this need. We look forward to working closely with Intermountain as we strive to bring the full promise of precision medicine to the treatment of patients."
For more information visit www.deepthinkhealth.com
Source: DeepThink Health
0 Comments
Latest on The Californer
- San Francisco Stress and Anxiety Center welcomes our Community Engagement Manager, Lisa Consiglio
- Tips for Choosing the Right Gold Rope Chain and Pendant
- Durham Record Label Maison Fauna Announces Its First Release
- Kansas City International Airport Adds Three BYD Buses
- Code-Analytics Innovator Merico Raises Seed-Round Led by GGV Capital to Empower Engineering Teams in a Post-Pandemic World
- Siembra Heritage Weaves Tradition & Fashion Together in Handmade, One-of-a-Kind Pieces
- AUA Announces Agreement with Texas's Schreiner University
- Axiomtek's Ultra Compact Network Appliance with 4 GbE LANs for IIoT Security Applications - NA346
- CMS issues the First Ever Guidance on Remote Patient Monitoring for proposed 2021 Physician Fee Schedule
- Smokescreen eyes a larger share of the global cybersecurity pie; appoints Preekshit Gupta as Head of Sales – India, MEA, and, APAC
- Evolve IP® Named For Eighth Time to the Inc. 5000 List of Fastest-Growing Private Companies
- 'Sommet Dame' Media Kit Reflects The Sophistication And Grace Of The Modern Woman
- Julia's headband wigs cheap human hair wigs for black women
- Netberg Joins Telecom Infra Project (TIP)
- Pat Brown Institute at Cal State LA honors California secretary of state
- Cal State LA Selects SELA Collaborative for the Statewide Civic Action Fellowship Program
- Wholesale Face Masks Brands And How To Work With Them
- Action Thriller 'Attraction to Paris' scores US deal
- Arrow Organics Reveals 20:1 CBD to THC Product Line
- Innovative Pain-Therapy Copper Cream Signals the Sufferer How to Get Best Pain Relief